In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Gunnar BirgegÃ¥rd discusses what we have learned so far regarding the use of JAK inhibitors in the treatment of essential thrombocythemia (ET) and polycythemia vera (PV).
A continuing education program related to this video is offered at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210
© 2016 Imedex, LLC.
Advertisement Single Between Content
Advertisement Single Between Content
Advertisement Single Between Content
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content